Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Solid State Nuclear Magnetic Resonance|March 6, 2014
Local-field approximation of homonuclear dipolar interactions in ⁷Li-NMR: density-matrix calculations and random-walk simulations tested by echo experiments on borate glassesMichael Storek, Kenneth R Jeffrey, Roland Böhmer
Current Medicinal Chemistry|May 13, 2017
Global View on Rare Diseases: A Mini ReviewBlanka Klimova, Michael Storek, Martin Valis, et al.
Clinical Pharmacology and Therapeutics|May 1, 2025
Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response AnalysesTimothy Chow, Marek Wardecki, Michael Storek, et al.
The Journal of Chemical Physics|October 2, 2012
NMR and conductivity studies of the mixed glass former effect in lithium borophosphate glassesMichael Storek, Roland Böhmer, Steve W Martin, et al.
The Journal of Physical Chemistry. B|April 20, 2016
Positive and Negative Mixed Glass Former Effects in Sodium Borosilicate and Borophosphate Glasses Studied by (23)Na NMRMichael Storek, Mischa Adjei-Acheamfour, Randilynn Christensen, et al.
Blood|August 24, 2011
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseasesMasha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, et al.
Blood|December 12, 2023
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b studyShirley D'Sa, Josephine M I Vos, Wilma Barcellini, et al.
Clinical Immunology (Orlando, Fla.)|May 6, 2023
Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1sKen T Simmons, Joanne Chan, Sami Hussain, et al.
Clinical and Translational Science|January 20, 2023
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitorTimothy Chow, Pirouz Shamszad, Christopher Vinnard, et al.
Blood Advances|March 10, 2023
SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor BbVaishnavi Rajagopal, Nina Leksa, Ronald Gorham, et al.
Pageof 2